Elaine Sullivan discusses Asset POLB 002 & Respiratory Viruses

Poolbeg’s Scientific Advisory Board member, Dr Elaine Sullivan discusses why respiratory viruses are such a global threat & why she is so excited about our recent asset acquisition, POLB 002, an RNA-based immunotherapy for respiratory virus infections.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.

Click to view all articles for the EPIC: POLB
Or click to view the full company profile:
Poolbeg Pharma plc

Poolbeg Pharma: GMP manufacturing contract signed

13th May 2022

Update on POLB 001 Clinical Development GMP manufacturing contract signed ensuring ample supply of POLB 001 for clinical development and for use in investigating further potential disease indications Poolbeg Pharma announced an update on its lead asset, POLB 001,

Poolbeg Pharma GMP manufacturing contract signed ensuring ample supply of POLB 001

12th May 2022

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced an update on its lead asset, POLB 001, a small molecule immunomodulator which aims to address a

Poolbeg to engage with key international stakeholders at Congress

11th May 2022

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, is participating in the European Melioidosis Congress (EMC) 2022, due to take place 16 May 2022 – 18 May 2022 in Graz,

Warwick University Professors Nigel Dimmock & Andrew Easton on POLB 002

4th May 2022

Covid battle bequeaths a priceless legacy of drugs to treat the next pandemic

29th April 2022

The pandemic is over, peaking in December with the arrival of the Omicron variant, and we were lucky it was a coronavirus and not another ’flu. This pandemic has petered out relatively quickly because most of the developed

Poolbeg Pharma strong shareholder confidence as Company enters clinical phase of development

27th April 2022

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced the results of the proposal from a number of New Investors to purchase shares from distribution in specie

Key POLB 002 European patent granted

26th April 2022

Investors to buy €1.9m shares in Poolbeg Pharma

20th April 2022

Infectious disease company Poolbeg Pharma has said a number of new investors have expressed interest in acquiring up to £1.6 million (€1.9m) of its shares which are currently locked up and held in trust by Croft Nominees. The investors have

Poolbeg Pharma granted an important patent

19th April 2022

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announced on Thursday an update on the strengthening of its intellectual property (IP) for its asset POLB 002, a first-in-class,

Poolbeg Pharma expands POLB 002 patent family with European Patent Office approval

14th April 2022

Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has provided an update on the strengthening of its intellectual property (IP) for its asset POLB 002, a first-in-class, intranasally administered

Poolbeg Pharma absolutely delighted with new investor interest

12th April 2022

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announced this week that a number of new investors have expressed interest in acquiring up to £1.6m of Poolbeg

CEO Jeremy Skillington on OTCQB listing

11th April 2022

Poolbeg Pharma new investors offer to purchase distribution in specie shares

11th April 2022

Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced that a number of new investors have expressed interest in acquiring up to £1.6m of Poolbeg Pharma plc shares

Poolbeg Pharma POLB 001 Clinical Development

4th April 2022

Poolbeg Pharma sign agreement with Centre for Human Drug Research in the Netherlands

31st March 2022

Poolbeg Pharma (LON:POLB, OTCQB: POLBF) has announced that it has signed a Clinical Trial Agreement with the Centre for Human Drug Research (CHDR) in the Netherlands for the completion of a bacterial lipopolysaccharide (‘LPS’) human challenge study of POLB 001,

Poolbeg Pharma commences trading on OTCQB Market in the United States

30th March 2022

Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced that trading in the Company’s Ordinary Shares of nominal value of £0.02 each will commence today on the OTCQB

Poolbeg Pharma signs deal with AI company on influenza data

28th March 2022

Infectious disease specialist Poolbeg Pharma has signed a deal with artificial intelligence company CytoReason to provide analysis of data from human challenge studies on influenza. The project, which is due to commence immediately,could yield new and better treatments for influenza.

Poolbeg Pharma results to 31 December 2021

15th March 2022

No more posts to show

Be sure to check our sister interview main ratings news website